Gain Therapeutics
View On Demand

A Cure For Parkinson's Is Unfolding Right Before Our Eyes

About the Event

Gain Therapeutics (NASDAQ: GANX) is transforming drug discovery with its AI and supercomputer-powered technology platform SEE-Tx.® SEE-Tx® accelerates the drug discovery process from more than 2 years to less than 3 months, unlocks new treatment approaches by enabling the identification of novel protein binding sites, and is currently being applied to develop GT-02287 a new drug for the treatment of Parkinson’s disease.

Gain is ready to move into a Phase 1 clinical trials to evaluate GT-02287 in healthy volunteers to assess safety and pharmacokinetics, with the goal of identifying an optimal dose level for Phase 1b and Phase 2 trials. In addition to GBA1-Parkinsons’s has therapeutic potential in multiple additional neurodegenerative diseases, including Gaucher disease, idiopathic Parkinson’s disease, Lewy body dementia, and Alzheimer’s, creating a total addressable market that exceeds $15B.

Join our webinar with Gain CEO, Matthias Adler, for an update on the company’s progress and details about their upcoming clinical trials.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.